Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
The Lancet. Haematology|July 18, 2025
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trialVania Hungria, Marek Hus, ChengCheng Fu, et al.
Haematologica|June 19, 2025
Radiopsy: a prospective observational study on quantitative multiparametric whole-body magnetic resonance imaging to discriminate between smoldering and multiple myelomaGiacomo Feliciani, Emiliano Loi, Elena Amadori, et al.
Seminars in Hematology|May 22, 2025
Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathyShirley D'Sa, Jahanzaib Khwaja, Signy Chow, et al.
Plos One|September 15, 2022
Correction: Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemiaAdrián Mosquera Orgueira, Andrés Peleteiro Raíndo, Miguel Cid López, et al.
Frontiers in Immunology|August 25, 2022
Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patientsSara Pasquina Pascale, Roberta Nuccorini, Teresa Pierri, et al.
Research Square|August 15, 2020
A large-scale database of T-cell receptor beta (TCRβ) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2Sean Nolan, Marissa Vignali, Mark Klinger, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2023
Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple MyelomaNatthakan Thongon, Feiyang Ma, Pamela Lockyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA StudySikander Ailawadhi, Ivan Špička, Andrew Spencer, et al.
Cancers|June 24, 2022
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 ProtocolMonica Messina, Alfonso Piciocchi, Tiziana Ottone, et al.
American Journal of Hematology|January 20, 2025
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating AgentsGiovanni Marconi, Elisabetta Petracci, Giuseppe Lanzarone, et al.
Pageof 13